Assembly Biosciences Inc (ASMB) Holdings Reduced by A.R.T. Advisors LLC

A.R.T. Advisors LLC decreased its holdings in Assembly Biosciences Inc (NASDAQ:ASMB) by 58.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 15,325 shares of the biopharmaceutical company’s stock after selling 21,600 shares during the period. A.R.T. Advisors LLC’s holdings in Assembly Biosciences were worth $753,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in Assembly Biosciences in the 1st quarter valued at about $154,000. Teacher Retirement System of Texas purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $242,000. MetLife Investment Advisors LLC purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $326,000. Endurant Capital Management LP purchased a new stake in Assembly Biosciences in the 4th quarter valued at about $430,000. Finally, American International Group Inc. grew its holdings in Assembly Biosciences by 15.4% in the 4th quarter. American International Group Inc. now owns 10,853 shares of the biopharmaceutical company’s stock valued at $491,000 after buying an additional 1,450 shares during the period. Institutional investors own 78.11% of the company’s stock.

ASMB opened at $39.29 on Friday. Assembly Biosciences Inc has a 12 month low of $18.60 and a 12 month high of $67.36. The stock has a market capitalization of $841.14 million, a price-to-earnings ratio of -16.67 and a beta of 0.79.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.11). Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $1.88 million. equities research analysts forecast that Assembly Biosciences Inc will post -3.54 earnings per share for the current fiscal year.

In other news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $49.32, for a total transaction of $49,320.00. Following the completion of the sale, the director now owns 20,465 shares in the company, valued at approximately $1,009,333.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 3,000 shares of company stock valued at $134,850 in the last quarter. Company insiders own 18.20% of the company’s stock.

Several analysts have commented on ASMB shares. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $72.00 price target for the company in a report on Tuesday, March 13th. BidaskClub cut Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, March 23rd. Chardan Capital cut Assembly Biosciences from a “buy” rating to a “neutral” rating and lifted their price target for the company from $35.00 to $50.00 in a report on Friday, April 13th. ValuEngine upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Jefferies Financial Group lifted their price target on Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $60.50.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply